This transaction
The MergerThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Operation of medical checkup and health screening centers, Operation of ophthalmology clinics, including myopia correction through LASIK surgery
The impact of the merger on consolidated results for the fiscal year ending March 2027 will be immaterial.
| Item | Details |
|---|---|
| Transaction name | The Merger |
| Counterparty name | Shinagawa Healthcare Solutions Corporation, Shinagawa Lasik & Aesthetics Center Corporation |
| Name of the Subject Company | Shinagawa Healthcare Solutions Corporation, Shinagawa Lasik & Aesthetics Center Corporation |
| Business Description of the Subject Company | Operation of medical checkup and health screening centers, Operation of ophthalmology clinics, including myopia correction through LASIK surgery |
| Location of the Subject Company | Taguig City, Metro Manila, Philippines, Taguig City, Metro Manila, Philippines |
| Capital Stock of the Subject Company | 350,000,000PHP, 232,396,015PHP |
| Date of Establishment of the Subject Company | 10 June 2022, 10 February 2010 |
| Net Sales of the Subject Company | PHP 237,161,347 (fiscal year ended December 2025), PHP 401,927,545 (fiscal year ended December 2025) |
| Operating Profit of the Subject Company | PHP (25,869,570) (fiscal year ended December 2025), PHP 47,424,067 (fiscal year ended December 2025) |
| Net Assets of the Subject Company | PHP 85,642,939 (fiscal year ended December 2025), PHP 916,083,186 (fiscal year ended December 2025) |
| Type of Consideration | Shares (shares of the surviving company allocated to shareholders of the disappearing company) |
| Voting rights ownership percentage | Before SHSC: 40% held by the Company; SLACC: 46.54% held by the Company → after Merged company: 48.47% held by the Company |
| Impact on Business Performance | The impact of the merger on consolidated results for the fiscal year ending March 2027 will be immaterial. |
| Date of board resolution | 20 November 2026 |
| Contract Date | December 2026 (予定) |
| Execution Date / Effective Date | 1 January 2027 (予定) |
| Valuation methodology | Based on the enterprise value appraisals of SHSC and SLACC by the local audit firm as of 30 September 2026, after the audit |
| Independent valuation institution | Local audit firm (name not disclosed) |
| Management structure after acquisition | The surviving company will be SHSC, which is scheduled to change its name to Shinagawa Medical Group following the merger. The representative will be President Masako Uemori (Senior Managing Director of the Company). Employee treatment is Not disclosed. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To integrate the businesses of the 2 companies, simplify the organizational structure, improve management efficiency by strengthening management and optimizing the consolidation and allocation of management resources, and establish a foundation for medium- to long-term growth and strengthen competitiveness.